NCT00267748 · Interventional trial
Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing As First-Line Therapy For Metastatic Renal Cell Cancer (RCC)
Overall registry status Completed
Phase 2
Conditions Carcinoma, Renal Cell
Delaware Valley sites
- Pfizer Investigational Site · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory